News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DelMar Pharmaceuticals Named to Rocket Builders' 2013 "Ready to Rocket" List


3/13/2013 9:55:53 AM

VANCOUVER, British Columbia and MENLO PARK, Calif., March 13, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the Company has been named to Rocket Builder's 11th annual "Ready to Rocket" list.

Rocket Builders "Ready to Rocket" list recognizes British Columbia technology companies that are best positioned to capitalize on the 2012 technology sector trends that will lead them to faster growth than their peers. According to Rocket Builders, the annual "Ready to Rocket" lists provide accurate predictions of companies that will likely experience significant growth, venture capital investment or acquisition by a major player in the coming year.

"Each year, our team of analysts received lots of inquiries on how we are able to predict so accurately which companies will grow revenue," said Geoffrey Hansen, Managing Partner at Rocket Builders. "Three elements characterize these high growth firms: a growing market opportunity, a unique competitive position and customer validation of a must-have value proposition."

"As a new public company, we are pleased to receive this important recognition of our recent accomplishments as we seek to implement our strategy to develop break-through cancer medicines for orphan cancer indications," stated Jeffrey Bacha, President & CEO of DelMar Pharma.

The 2013 list features 10 companies, and the list can be found here: http://www.readytorocket.com/2013/03/2013-ready-to-rocket-life-science-list.html.

According to Thealzel Lee, Senior Partner at Rocket Builders, "We are pleased to include DelMar Pharma in our Ready to Rocket list for 2013. DelMar's recent corporate accomplishments position the company for leadership in the British Columbia life sciences community. 2012 has seen significant investments in British Columbia's life science companies as well as changes to the business landscape that is reflective of the challenges faced by the regulatory environment as it tries to keep up with the advances and convergence of molecular biology, chemistry, digital media, nanotechnology, ICT and other interfacing technologies."

For details on the "Ready to Rocket" lists, please visit http://www.readytorocket.com.

About the Rocket Recognition Program
The Rocket Recognition Program features two branded lists of companies. The "Ready to Rocket" list profiles information technology companies with the greatest potential for revenue growth in the coming year. The "Emerging Rockets" list profiles technology companies from multiple technology sectors with great potential for investment and market breakthroughs in the coming year. Both lists are predictive of future success making them unique in approach and unique in value for our business audience. "Ready to Rocket" and "Emerging Rockets" are trademarks of Rocket Builders, a respected management-consulting firm servicing the technology industry. http://www.readytorocket.com.

About Rocket Builders
Rocket Builders is a management-consulting firm providing sales and marketing services. With a focus on helping technology companies to grow and prosper, Rocket Builders has a proven track record of success with its clients. Since 2000, we have been engaged in market research, market planning, business development initiatives, strategic selling, and product launches for over 200 organizations. http://www.rocketbuilders.com.

Media Contact
Jody Rebak, tel: 778.231.6990
Rocket Builders

About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha, President & CEO (604) 629-5989 or Booke & Company Investor Relations, admin@bookeandco.com.

SOURCE DelMar Pharmaceuticals, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES